Characterization and therapeutic perspectives of differentiation-inducing therapy in malignant tumors

Front Genet. 2023 Sep 8:14:1271381. doi: 10.3389/fgene.2023.1271381. eCollection 2023.

Abstract

Cancer is a major public health issue globally and is one of the leading causes of death. Although available treatments improve the survival rate of some cases, many advanced tumors are insensitive to these treatments. Cancer cell differentiation reverts the malignant phenotype to its original state and may even induce differentiation into cell types found in other tissues. Leveraging differentiation-inducing therapy in high-grade tumor masses offers a less aggressive strategy to curb tumor progression and heightens chemotherapy sensitivity. Differentiation-inducing therapy has been demonstrated to be effective in a variety of tumor cells. For example, differentiation therapy has become the first choice for acute promyelocytic leukemia, with the cure rate of more than 90%. Although an appealing concept, the mechanism and clinical drugs used in differentiation therapy are still in their nascent stage, warranting further investigation. In this review, we examine the current differentiation-inducing therapeutic approach and discuss the clinical applications as well as the underlying biological basis of differentiation-inducing agents.

Keywords: cell cycle; cell differentiation; differentiation mechanisms; differentiation-inducing therapy; retinoic acid.

Publication types

  • Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from the National Nature Science Foundation of China (Nos 81903055, 82173208, 82373365, 82173317, and 82103672), Natural Science Foundation of Tianjin, China (21JCQNJC01290) and Health Science and Technology Project of Tianjin, China (TJWJ2022MS008 and TJWJ2022QN105). Tianjin Key Medical Discipline (Specialty) Construction Project (No. TJYXZDXK-009A).